[go: up one dir, main page]

WO2000037067A3 - Sensitizing agents for the treatment of skin lesions - Google Patents

Sensitizing agents for the treatment of skin lesions Download PDF

Info

Publication number
WO2000037067A3
WO2000037067A3 PCT/US1999/030875 US9930875W WO0037067A3 WO 2000037067 A3 WO2000037067 A3 WO 2000037067A3 US 9930875 W US9930875 W US 9930875W WO 0037067 A3 WO0037067 A3 WO 0037067A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin lesions
treatment
sensitizing agents
lesion
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/030875
Other languages
French (fr)
Other versions
WO2000037067A2 (en
WO2000037067A9 (en
Inventor
Harry Goldberg
Hugh Sampson
Howard B Sosin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seer Pharmaceuticals LLC
Original Assignee
Panacea Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals LLC filed Critical Panacea Pharmaceuticals LLC
Priority to JP2000589178A priority Critical patent/JP2002532547A/en
Priority to AU23871/00A priority patent/AU770464B2/en
Priority to EP99967615A priority patent/EP1140052A2/en
Priority to CA002357413A priority patent/CA2357413A1/en
Publication of WO2000037067A2 publication Critical patent/WO2000037067A2/en
Publication of WO2000037067A9 publication Critical patent/WO2000037067A9/en
Publication of WO2000037067A3 publication Critical patent/WO2000037067A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compositions and methods for treating skin lesions by contacting the lesion with a sensitizing agent capable of eliciting a local immune response in the individual suffering from the lesion. The inventive compositions and methods may be applied in pharmaceutical and/or veterinary contexts.
PCT/US1999/030875 1998-12-22 1999-12-22 Sensitizing agents for the treatment of skin lesions Ceased WO2000037067A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000589178A JP2002532547A (en) 1998-12-22 1999-12-22 Treatment of skin lesions
AU23871/00A AU770464B2 (en) 1998-12-22 1999-12-22 Treatment of skin lesions
EP99967615A EP1140052A2 (en) 1998-12-22 1999-12-22 Sensitizing agents for the treatment of skin lesions
CA002357413A CA2357413A1 (en) 1998-12-22 1999-12-22 Sensitizing agents for the treatment of skin lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21834598A 1998-12-22 1998-12-22
US09/218,345 1998-12-22

Publications (3)

Publication Number Publication Date
WO2000037067A2 WO2000037067A2 (en) 2000-06-29
WO2000037067A9 WO2000037067A9 (en) 2000-11-23
WO2000037067A3 true WO2000037067A3 (en) 2001-01-18

Family

ID=22814736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030875 Ceased WO2000037067A2 (en) 1998-12-22 1999-12-22 Sensitizing agents for the treatment of skin lesions

Country Status (5)

Country Link
EP (1) EP1140052A2 (en)
JP (1) JP2002532547A (en)
AU (1) AU770464B2 (en)
CA (1) CA2357413A1 (en)
WO (1) WO2000037067A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10331974A1 (en) * 2003-07-14 2005-02-17 Uni-Klinikum Schleswig-Holstein Campus Kiel Method of making and using antimicrobial protein-inducing factors
EP2185145A1 (en) * 2007-04-04 2010-05-19 Board of Trustees of the University of Arkansas Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
KR102499738B1 (en) 2009-08-26 2023-02-13 마리 케이 인코포레이티드 Topical skin care formulations comprising plant extracts
NL2003419C2 (en) * 2009-09-01 2011-03-02 Shieldmark Zacco Composition for tropical application, uses thereof, applicator device and kit of parts.
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN105188741A (en) 2013-04-03 2015-12-23 阿勒丁医疗公司 Novel nanoparticle compositions
KR102533463B1 (en) 2015-02-26 2023-05-16 스퀘어렉스 파마슈티컬 코포레이션 Non-specific delayed-type hypersensitivity reaction to treat herpes simplex virus infection
WO2019160942A1 (en) * 2018-02-13 2019-08-22 Hamann Curt Patches comprising urushiol, test panels comprising the same, and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279382A2 (en) * 1987-02-18 1988-08-24 Brigitte Lünemann Wart cure
WO1993008832A1 (en) * 1991-11-08 1993-05-13 Dallas Biotherapeutics, Inc. Stabilization of human interferon
KR19980067871A (en) * 1997-02-13 1998-10-15 박원훈 New use of anti-cancer agent including antioxidant activity of urushiol compound and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279382A2 (en) * 1987-02-18 1988-08-24 Brigitte Lünemann Wart cure
WO1993008832A1 (en) * 1991-11-08 1993-05-13 Dallas Biotherapeutics, Inc. Stabilization of human interferon
KR19980067871A (en) * 1997-02-13 1998-10-15 박원훈 New use of anti-cancer agent including antioxidant activity of urushiol compound and preparation method thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHITINS M.P. ET AL: "Anti-tumour activity of the extract of Semecarpus anacardium L. nuts in experimental tumour models", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 18, 1980, pages 6 - 8, XP000885431 *
DATABASE WPI Section Ch Week 199951, Derwent World Patents Index; Class B05, AN 1999-599559, XP002136218 *
JARISCH R. ET AL: "MIF in der Therapiekontrolle von Herpes simplex recidivans: Behandlung mit Levamisole, BCG, Urushiol und Herpes Antigen Vaccine", ARCHIV FÜR DERMATOLOGISCHE FORSCHUNG, vol. 258, 1977, pages 151 - 159, XP000885433 *
KUDI A.C. ET AL: "Antiviral activity of some Nigerian medicinal plant extracts.", JOURNAL OF ETHNOPHARMACOLOGY, (1999) 68/1-3 (289-294)., XP000885472 *
NAKANO M ET AL: "Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs [published erratum appears in Antiviral Res 1999 Apr;41(3):153-4].", ANTIVIRAL RESEARCH, (1998 JUL) 39 (1) 25-33., XP000885489 *
SMIT H.F. ET AL: "Ayurvedic herbal drugs with possible cytostatic activity", JOURNAL OF ETHNOPHARMACOLOGY, vol. 47, 1995, pages 75 - 84, XP000885469 *

Also Published As

Publication number Publication date
WO2000037067A2 (en) 2000-06-29
AU2387100A (en) 2000-07-12
JP2002532547A (en) 2002-10-02
AU770464B2 (en) 2004-02-19
WO2000037067A9 (en) 2000-11-23
EP1140052A2 (en) 2001-10-10
CA2357413A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
MY119711A (en) Method of inhibiting photoaging of skin
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2002001499A3 (en) Cosmetic treatment method and device, in particular for care, make-up or colouring
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
NO20004098D0 (en) Methods and preparations for the treatment of macrophage-mediated disorders
FI971969A0 (en) Compositions and method of use for the treatment of hemorrhoids
AU2212299A (en) Compositions and methods for the treatment of tumor
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
SE9603725D0 (en) New teatment
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
WO2000037067A3 (en) Sensitizing agents for the treatment of skin lesions
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
NO992504L (en) Compositions for the treatment of soil, process for its preparation, and use
NL1010351A1 (en) Esters of carotenoids for use in the prevention and treatment of eye diseases.
EP0744176A3 (en) Methods for inhibiting bone loss

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 23871/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 589178

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2357413

Country of ref document: CA

Ref country code: CA

Ref document number: 2357413

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999967615

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967615

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 23871/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999967615

Country of ref document: EP